PT-141 (Bremelanotide) for Endurance Athletes: Protocol, Dosing, and Evidence

What PT-141 (Bremelanotide) Is and How It Works in Athletes

PT-141 acts centrally on melanocortin receptors in the hypothalamus and limbic system rather than on vascular smooth muscle, which is how it differs mechanistically from phosphodiesterase-5 inhibitors. This central mechanism is why researchers initially developed it as a possible treatment for sexual dysfunction and why some athletes consider it when high training loads blunt hypothalamic signaling.

Endurance training at volumes typical of competitive triathlon or marathon preparation (greater than 12 to 15 hours per week) can suppress the hypothalamic-pituitary-gonadal (HPG) axis. That suppression reduces luteinizing hormone (LH) pulse amplitude, lowers testosterone and estradiol, and frequently produces low libido well before a formal diagnosis of relative energy deficiency in sport (RED-S) is made. Mountjoy et al., British Journal of Sports Medicine, 2018 define this HPG suppression as a core clinical feature of RED-S across both male and female athletes.

The Melanocortin System and Sexual Function

The melanocortin system coordinates energy balance, stress response, and reproductive behavior. MC4R activation in the paraventricular nucleus of the hypothalamus produces pro-sexual and appetite-suppressing signals. King et al. (2007) demonstrated in a placebo-controlled crossover study (N=20 men with erectile dysfunction) that bremelanotide produced statistically significant increases in erectile activity vs. Placebo (P<0.001), confirming central nervous system-mediated action.

Why Athletes Use It Off-Label

Libido suppression in high-volume athletes is common and under-reported. A survey published in the British Journal of Sports Medicine (2021) found that 51% of elite female endurance athletes reported low sexual desire during peak training blocks. Male athletes are not exempt: overreaching-associated testosterone suppression has been documented in studies showing a 30% reduction in free testosterone after four weeks of intensified cycling training. Meeusen et al. (2013) established these overtraining biomarkers in the European College of Sport Science and American College of Sports Medicine consensus statement on overtraining syndrome.

PT-141 does not repair the underlying energy deficit or restore HPG axis function. It transiently activates melanocortin receptors to produce a libido signal that training volume has suppressed. Clinicians who prescribe it off-label for athletes frame it as a symptomatic bridge while the athlete addresses training load, caloric adequacy, and sleep.

FDA Approval, Legal Status, and Athlete Considerations

The FDA approved bremelanotide (Vyleesi) on June 21, 2019, specifically for premenopausal women with acquired, generalized HSDD. FDA prescribing information for Vyleesi defines the approved dose as 1.75 mg subcutaneous injection administered 45 minutes before anticipated sexual activity, with a maximum frequency of once per 24 hours and no more than 8 doses per month.

WADA and Anti-Doping Status

PT-141 is not currently listed on the World Anti-Doping Agency (WADA) 2024 Prohibited List. It does not appear on the USADA prohibited substance list as of the date of this review. Athletes competing under anti-doping frameworks should verify status independently before use, as the prohibited list is updated annually. The FDA has not approved PT-141 for men, making any male use off-label regardless of athletic status.

Compounded vs. FDA-Approved Formulations

Many athletes obtain bremelanotide through compounding pharmacies rather than the commercial Vyleesi product. Compounded versions are not FDA-approved and lack the quality-control data of the commercial product. FDA guidance on compounded drug products notes that compounded drugs may vary in potency, sterility, and stability. This is a material clinical risk for subcutaneous peptide use.

Structured Protocol for Endurance Athletes

No published endurance-sport-specific protocol exists. The following is derived from the FDA-approved prescribing information, published HSDD RCT data, and practitioner experience documented in peer-reviewed commentary. Every element is labeled by evidence level.

Dose Selection

| Patient Profile | Starting Dose | Titration Target | Evidence Level | |---|---|---|---| | Female athlete, HSDD diagnosis confirmed | 1.75 mg SC | Maintain if tolerated; reduce to 1.0 mg if nausea is limiting | RCT (Level 1b) | | Male athlete, off-label, physician-supervised | 0.5 mg SC | Titrate to 1.0 mg; 2.0 mg is practitioner ceiling | Observational / expert opinion (Level 4) | | Any athlete, high nausea sensitivity | 0.5 mg SC | Titrate by 0.25 mg increments with antiemetic pretreatment | Expert opinion (Level 5) |

The key Phase 3 RECONNECT trials (two identical RCTs, combined N=1,267 premenopausal women) tested 1.75 mg bremelanotide vs. Placebo across 24 weeks. Clayton et al. (2016) reported statistically significant improvements in the Female Sexual Function Index (FSFI) desire domain (P<0.001) and distress scores (P<0.001) vs. Placebo. These are the trials that supported FDA approval and set the dose anchor for clinical use.

Timing and Administration

Inject subcutaneously into the abdomen or thigh 45 minutes before intended sexual activity. The pharmacokinetic profile shows peak plasma concentration at approximately 1 hour post-injection, with a half-life of approximately 2.7 hours. Molinoff et al. (2003) characterized this profile in early intranasal bremelanotide studies; the subcutaneous formulation achieves similar Tmax with better bioavailability than intranasal delivery.

Do not administer immediately before or after intense training sessions. Nausea is dose-dependent and peaks within the first 60 minutes; combining this with post-workout dehydration or glycogen depletion worsens GI tolerance. An athlete finishing a long ride and using PT-141 that evening should eat a full recovery meal and rehydrate before injection.

Cycle Length and Frequency

The FDA label caps use at 8 doses per 28-day period (roughly twice per week). For athletes using it off-label as a training-block bridge, a structured approach is:

• Active use period: 4 to 8 weeks during peak training phase when libido suppression is symptomatic
• Frequency: 1 to 2 doses per week, as needed, not prophylactically
• Rest period: 4 weeks off after each active cycle before reassessing symptom status
• Discontinuation trigger: Resumption of spontaneous desire, resolution of training overreach, or cardiovascular side effects

No data support continuous use beyond the 24-week RECONNECT trial window. Longer durations in the absence of ongoing HSDD diagnosis are not currently supported by published evidence.

Blood Pressure Monitoring

Bremelanotide causes a transient mean increase in systolic blood pressure of approximately 6 mmHg and diastolic blood pressure of approximately 3 mmHg, peaking at approximately 4 hours post-dose and resolving by 12 hours. FDA prescribing information requires that it not be used in patients with cardiovascular disease for this reason. Endurance athletes typically have lower resting blood pressure than the general population, which may blunt clinical significance of this transient rise, but baseline measurement before initiating use is still required.

Monitoring Labs and Clinical Assessment

Baseline Labs Before Starting

Any physician-supervised PT-141 protocol in an endurance athlete should include the following before the first dose:

• Resting blood pressure (two readings on separate days)
• Comprehensive metabolic panel (renal and hepatic function)
• Fasting lipids (cardiovascular risk stratification)
• Total and free testosterone (male and female athletes)
• LH and FSH (to characterize HPG axis suppression pattern)
• Estradiol (female athletes)
• Prolactin (to exclude hyperprolactinemia as alternate cause of low libido)
• TSH (thyroid dysfunction is a common and treatable cause of low libido)

The Endocrine Society Clinical Practice Guideline on Female Sexual Dysfunction (2019) recommends ruling out thyroid dysfunction, hyperprolactinemia, and androgen insufficiency before attributing HSDD to any other cause. That diagnostic sequence applies equally in athletes.

Athlete-Specific Lab Additions

For endurance athletes, add:

• Ferritin (iron deficiency independently reduces libido and is endemic in distance runners)
• Vitamin D (25-OH) (deficiency associated with mood and libido suppression; Wehr et al., 2009 found 25-OH vitamin D levels positively correlated with testosterone in men, N=2,299)
• Cortisol AM (chronic overreaching elevates baseline cortisol, which suppresses GnRH)
• CRP or ESR (systemic inflammation baseline before introducing any peptide)

Follow-Up Assessment at 6 to 8 Weeks

Repeat blood pressure. Assess nausea severity, response quality, and any new cardiovascular symptoms. Re-administer the FSFI (women) or the IIEF-5 (men) to quantify change from baseline. If total testosterone has risen spontaneously at follow-up, that finding suggests training load or energy availability, not melanocortin signaling, was the primary driver, and PT-141 may not be the appropriate long-term tool.

Expected Timeline of Outcomes

Acute Effects (Dose 1 to Dose 3)

The central melanocortin signal is generated within the first hour post-injection. Most patients in the RECONNECT trials reported awareness of desire change within 60 minutes of the first dose. Nausea, when it occurs, is also most severe with early doses. Simon et al. (2014) reported that nausea in the RECONNECT program occurred in 40.0% of bremelanotide users vs. 8.0% of placebo users, with severity decreasing after the first two to three doses.

Short-Term Effects (Weeks 2 to 8)

Sustained improvement in desire domain scores on validated instruments was detectable by week 4 in the RECONNECT data. The trials excluded women whose HSDD was attributed to relationship factors or general medical conditions, a selection criterion that does not apply cleanly to athletes whose suppression is training-load-driven. This gap between trial population and athlete population is a material evidence limitation.

Medium-Term Considerations (Beyond 8 Weeks)

If libido does not normalize after 8 weeks of PT-141 use combined with training load reduction, clinicians should investigate RED-S more formally. The IOC Consensus Statement on RED-S (2023) provides a clinical assessment tool (LEAF-Q and RED-S CAT) for systematically quantifying energy deficiency severity. Symptom persistence despite PT-141 use is a signal to address the underlying physiology, not to escalate the dose.

Side Effects, Contraindications, and Drug Interactions

Nausea Management

Nausea is the most common reason for discontinuation. Taking ondansetron 4 mg orally 30 minutes before PT-141 injection substantially reduces nausea severity based on practitioner experience, though no RCT has tested this combination specifically. Avoid high-fat meals immediately before injection; the FDA label notes that a high-fat meal increases bremelanotide AUC by approximately 24%, potentially worsening side effects without improving efficacy proportionally. FDA prescribing information recommends administration without regard to food but acknowledges this AUC interaction.

Hyperpigmentation

MC1R agonism from bremelanotide can cause focal hyperpigmentation, particularly on the face, gums, and breasts, with repeated use. The FDA label lists this as a known risk. Athletes spending extended time outdoors in sun exposure may notice this more readily. Darkening typically resolves within a few weeks after discontinuation, though FDA prescribing information does not guarantee complete reversal with long-term use.

Absolute Contraindications

Per FDA labeling and cardiovascular pharmacology:

• Known cardiovascular disease (coronary artery disease, stroke, uncontrolled hypertension)
• Concurrent use of high-dose alkyl nitrates (poppers)
• Known hypersensitivity to bremelanotide or any excipient
• Use in pregnant women (animal studies show fetal harm at supratherapeutic doses)

Drug Interactions

Bremelanotide slows gastric emptying and may reduce absorption of orally administered drugs taken concurrently. FDA prescribing information specifically flags this for narrow-therapeutic-index drugs (e.g., naltrexone extended-release). Athletes using oral NSAIDs, oral contraceptives, or oral thyroid replacement around the same window should time administration separately.

Situating PT-141 Within an Endurance Athlete's Broader Hormonal Picture

PT-141 addresses one symptom of HPG axis suppression. It does not correct low testosterone, restore LH pulsatility, or repair the energy availability deficit driving RED-S. The decision framework below describes how an endurance-medicine physician might position PT-141 relative to other interventions:

Step 1. Confirm energy availability. Calculate energy availability (EA) using Mountjoy et al. (2023) RED-S criteria. EA below 30 kcal/kg FFM/day is the primary target. No symptomatic peptide use is appropriate without first addressing this.

Step 2. Rule out primary causes. TSH, prolactin, and morning cortisol should be normal before attributing low libido to training-load-driven melanocortin suppression. The Endocrine Society guideline (2019) makes this point explicitly: "HSDD should be diagnosed only after other medical and psychiatric etiologies have been excluded."

Step 3. Optimize sleep and training load. Sleep restriction to fewer than 7 hours per night reduces testosterone by 10 to 15% within one week. Leproult and Van Cauter (2011) documented this in a prospective study (N=10 healthy young men) published in JAMA. Before adding any peptide, athletes should reduce weekly training volume by 20 to 30% and target 8 to 9 hours of sleep for 2 weeks to see whether libido spontaneously improves.

Step 4. Consider PT-141 as a time-limited bridge. If EA is adequate, primary endocrine causes are excluded, sleep and load are optimized, and low libido persists, PT-141 at 0.5 to 1.75 mg subcutaneous as needed (maximum 8 doses per month) may be appropriate under physician supervision for a defined 4 to 8-week cycle.

Step 5. Reassess at cycle end. Repeat hormonal labs. If testosterone and LH remain suppressed, refer to an endocrinologist for formal RED-S evaluation. PT-141 should not be continued indefinitely as a substitute for treating the underlying condition.

Evidence Summary and Limitations

The evidence supporting PT-141 use in endurance athletes specifically is weak. The strongest available data come from the RECONNECT program RCTs in premenopausal women with HSDD, which are Level 1b evidence for that specific population. Clayton et al. (2016) and Simon et al. (2014) together provide the pharmacodynamic and efficacy foundation. Melanocortin receptor physiology studied in animal models and early human trials provides mechanistic plausibility for HPG-suppressed athletes, but mechanistic plausibility is not clinical evidence.

No published RCT has enrolled endurance athletes, measured training-load-driven libido suppression as a primary endpoint, or tested PT-141 against placebo in that context. The off-label use in male athletes is entirely extrapolated from female HSDD data and basic science. Pfaus et al. (2007) reviewed melanocortin agonists and sexual behavior in animal models, providing the pre-clinical rationale that has been translated cautiously to human practice.

Practitioners using PT-141 off-label in athletes should document informed consent explicitly, including the absence of endurance-specific evidence, the cardiovascular blood pressure risk, and the distinction between the approved (female HSDD) and off-label (athlete, male) populations. The FDA MedWatch system should be used to report any unexpected adverse events.